Tarsus Pharmaceuticals, Inc. TARS Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s unrealized gains on investments?
- Tarsus Pharmaceuticals, Inc. (TARS) reported unrealized gains on investments of $91K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s unrealized gains on investments changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s unrealized gains on investments decreased by 19.5% year-over-year, from $113K to $91K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s unrealized gains on investments?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s unrealized gains on investments has grown at a 178.5% compound annual growth rate (CAGR), from $18K to $389K.
- What does unrealized gains on investments mean?
- The total increase in value of investment securities held by the company that have not yet been sold. This figure represents paper gains on the investment portfolio and is typically reported within accumulated other comprehensive income.